The Multinational Association of Supportive Care in Cancer (MASCC) shared a post on LinkedIn:
“Febrile neutropenia (FN) is common in patients treated with chemotherapy/ICI therapy, and risk stratifying patients with FN is essential to personalize acute management and optimize use of healthcare resources.
The MASCC score is well validated for risk stratification in FN, and patients with a score ≥ 21 are likely to be suitable for outpatient management. However, this tool has not been validated in patients treated with combined chemotherapy/ICI regimens.
This new MASCC position paper from Tim Cooksley and colleagues outlines an approach for acute ambulatory management of low-risk FN in this cohort.”
Title: Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement
Authors: Tim Cooksley, Carme Font, Karin Thursky, Bernardo Rapoport, Claire Falandry, Florian Scotte
Read the Full Article on Supportive Care in Cancer
Other posts about MASCC on OncoDaily.